FDA Reviewers Question Trial Results for AbbVie, UCB TNF-Blockers

Positive results from a clinical trial supporting a new indication for AbbVie’s arthritis drug Humira may have been skewed by a subgroup of patients meeting the criteria for ankylosing spondylitis (AS), an indication for which the drug is already approved, FDA reviewers say.
Drug Industry Daily